UTHR:NGS-United Therapeutics Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 255.14

Change

+20.81 (+8.88)%

Market Cap

USD 5.48B

Volume

1.41M

Analyst Target

USD 144.78
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.15 (+0.72%)

USD 109.10B
REGN Regeneron Pharmaceuticals Inc

-10.23 (-1.05%)

USD 107.30B
MRNA Moderna Inc

+3.62 (+2.80%)

USD 44.96B
ARGX argenx NV ADR

-0.36 (-0.10%)

USD 22.43B
BNTX BioNTech SE

+0.78 (+0.85%)

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

+3.82 (+2.59%)

USD 18.64B
BGNE BeiGene Ltd

+6.15 (+3.73%)

USD 18.28B
GMAB Genmab AS

-0.57 (-1.89%)

USD 18.26B
BMRN Biomarin Pharmaceutical Inc

-3.43 (-4.27%)

USD 15.29B
TECH Bio-Techne Corp

-0.66 (-0.79%)

USD 13.26B

ETFs Containing UTHR

MUUSAS:SW UBS (Irl) Fund Solutions .. 195.50 % 0.00 %

+1.40 (+0%)

USD 0.43B
PJP Invesco Dynamic Pharmaceu.. 4.41 % 0.56 %

-0.06 (0%)

USD 0.27B
SANE 4.17 % 0.00 %

N/A

N/A
SRHQ Elevation Series Trust - .. 1.76 % 0.00 %

-0.02 (0%)

USD 0.14B
KRUZ 1.45 % 0.00 %

N/A

N/A
DSMC ETF Series Solutions 1.42 % 0.00 %

-0.14 (0%)

USD 0.06B
JMEE JPMorgan Market Expansion.. 0.73 % 0.00 %

-0.23 (0%)

USD 1.09B
ETHO Etho Climate Leadership U.. 0.00 % 0.45 %

-0.18 (0%)

USD 0.18B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.17 (+0%)

USD 1.11B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FNX First Trust Mid Cap Core .. 0.00 % 0.62 %

-1.05 (0%)

USD 1.19B
FXH First Trust Health Care A.. 0.00 % 0.63 %

-0.43 (0%)

USD 1.25B
GURU Global X Guru Index ETF 0.00 % 0.75 %

-0.14 (0%)

USD 0.04B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.03 (+0%)

USD 0.10B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.40 (0%)

USD 0.02B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.06 (0%)

USD 8.18M
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.10 (+0%)

USD 0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.04 (0%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
GLRY Inspire Faithward Mid Cap.. 0.00 % 0.00 %

-0.28 (0%)

USD 0.06B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

+0.26 (+0%)

CAD 0.01B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-4.00 (0%)

USD 6.57M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

-0.05 (0%)

USD 6.57M
KONG Formidable Fortress ETF 0.00 % 0.00 %

+0.03 (+0%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.03% 70% C- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.03% 70% C- 81% B-
Trailing 12 Months  
Capital Gain 16.82% 72% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.82% 72% C 69% C-
Trailing 5 Years  
Capital Gain 158.66% 91% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 158.66% 90% A- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 29.89% 79% B- 85% B
Dividend Return 29.89% 79% B- 85% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.15% 81% B- 59% D-
Risk Adjusted Return 95.98% 100% F 96% N/A
Market Capitalization 5.48B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.80 40% 63%
Price/Book Ratio 1.83 64% 50%
Price / Cash Flow Ratio 11.25 5% 23%
Price/Free Cash Flow Ratio 6.24 4% 33%
Management Effectiveness  
Return on Equity 18.27% 98% 88%
Return on Invested Capital 14.58% 89% 84%
Return on Assets 11.22% 99% 96%
Debt to Equity Ratio 5.01% 62% 77%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector